David Wilson

ORCID: 0000-0002-6563-2979
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hepatocellular Carcinoma Treatment and Prognosis
  • MRI in cancer diagnosis
  • Gastric Cancer Management and Outcomes
  • Hip and Femur Fractures
  • Cardiac Arrest and Resuscitation
  • Urticaria and Related Conditions
  • Bone fractures and treatments
  • Pancreatic and Hepatic Oncology Research
  • Lung Cancer Treatments and Mutations
  • Pharmacological Effects of Natural Compounds
  • Orthopedic Surgery and Rehabilitation
  • Acute Kidney Injury Research
  • Gout, Hyperuricemia, Uric Acid
  • Global Cancer Incidence and Screening
  • Orthopaedic implants and arthroplasty
  • Colorectal Cancer Screening and Detection
  • Colorectal Cancer Surgical Treatments
  • Economic and Financial Impacts of Cancer

United States Food and Drug Administration
2022

University of Leeds
2020

Cleveland Clinic
2015

University of Missouri
2007

Manchester Royal Infirmary
2005

Purpose: Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. The aim this study was to evaluate pharmacokinetics, pharmacodynamics, tolerability verinurad healthy adult males. Subjects methods: This Phase I, randomized, double-blind, placebo-controlled, single multiple ascending dose study. Panels eight male subjects received oral or placebo either fasted fed state; panels 10–12 doses...

10.2147/dddt.s140658 article EN cc-by-nc Drug Design Development and Therapy 2017-07-01

Abstract Background: Preclinical data revealed a synergistic interaction between sorafenib (Nexavar®) and BAY 86-9766 (RDEA119). Sorafenib is an oral, small molecule, multikinase inhibitor that approved for the treatment of unresectable hepatocellular carcinoma (HCC) advanced renal cell carcinoma. investigational, potent, non-ATP competitive, highly selective MEK1/2. In Phase 1 single-agent trial in cancer patients, maximum tolerated dose (MTD) was 100 mg daily, given as 50 twice daily (bid)...

10.1158/1535-7163.targ-11-a88 article EN Molecular Cancer Therapeutics 2011-11-01

The purpose of this investigation was to design and verify the capabilities an in vitro loading-measurement system that mimics vivo unconstrained three dimensional (3D) relative motion between long bone ends, applies uniform load components over entire length a test specimen, measures 3D segment ends directly determine construct stiffness free errors due potting-fixture-test machine finite stiffness.Intact equine cadaveric radius bones, which were subsequently osteotomized/ostectomized...

10.1186/1749-799x-2-21 article EN cc-by Journal of Orthopaedic Surgery and Research 2007-11-24

Colorectal cancer (CRC) is the third most common in men, and second women UK. The aim of this book to address issues surrounding disease, provide nurses with up-to-date accurate information enable competent informed nursing care delivery.

10.7748/cnp.4.7.21.s18 article EN Cancer Nursing Practice 2005-09-01

10.1016/s0002-9440(19)30551-6 article EN publisher-specific-oa American Journal Of Pathology 2019-07-22

525 Background: During the COVID19 pandemic, many centres in UK, shifted towards utilising hypofractionated radiotherapy (RT) to pancreas. We aim report UK experience pancreas 2020. Methods: retrospectively identified patients receiving either moderate (15 fractions) or ultra-hypofractionated (3-5 RT from 7 UK. Rates of toxicity, progression, death and potential prognostic factors were assessed. Univariate multivariate Cox proportional hazards analyses performed. Results: 92 included...

10.1200/jco.2022.40.4_suppl.525 article EN Journal of Clinical Oncology 2022-01-19
Coming Soon ...